Join the Conversation on
11 people
0 stories
2 posts
Explore Our Newsletters
What's New in

Ampligen update: bad news for all of us w/ M.E. and Long Covid

I'm just so freaking worn out. Here's the latest re the current Ampligen trial.

For those who might not know, Ampligen is often referred to as "the Lazarus drug" b/c in its previous trials it has effectively combatted Post-Exertional Malaise.

However, it can sometimes cause liver damage. As such, a debate has swirled around Ampligen for decades and, indeed, some Myalgic Encephalomyelitis advocates think the risk of liver damage has been over-interpreted.

After a particularly horrid week, I was so hoping we'd all get some good news re the Ampligen trial. And I still believe it could be modified in a way that maintains its efficacy w/out causing severe side effects.

I do know that there's a massive financial incentive to develop a long-lasting treatment for both Myalgic Encephalomyelitis and for Long Covid b/c w/ tens of millions of us out of commission in the U.S. alone, well, someone's gonna get rich if they can treat us.

Damn post-viral illnesses straight to hell.

Day 54 of 365

AIM’s ampligen stumbles in Phase II trial

#MyalgicEncephalomyelitis #longcovid #ChronicFatigueSyndrome #cfsisamisnomer #ChronicIllness #PostexertionalMalaise #Ampligen #Disability #Ampligen

AIM’s ampligen stumbles in Phase II trial

AIM’s Ampligen failed to meet its primary endpoint in the Phase II trial in people with post-Covid fatigue.
6 reactions 2 comments